Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ICAM-1 monoclonal antibody
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
An anti-ICAM-1 monoclonal antibody is a type of targeted biologic therapy designed to bind to Intercellular Adhesion Molecule-1 (ICAM-1, also known as CD54). ICAM-1 is a cell surface glycoprotein expressed on endothelial cells, epithelial cells, and immune cells, playing a key role in leukocyte adhesion, migration, and inflammatory responses. It also serves as the entry receptor for major group rhinoviruses (such as RV16). Blocking ICAM-1 with monoclonal antibodies has been investigated for various therapeutic indications, including the prevention of transplant rejection, treatment of ischemic stroke, rheumatoid arthritis, multiple myeloma, and viral respiratory infections.
- Other names
- anti-CD54 mAbanti-CD-54 mAbanti-CD 54 mAbanti-CD54 monoclonal antibodyanti-CD-54 monoclonal antibodyanti-CD 54 monoclonal antibodyanti-ICAM-1 mAbanti-ICAM1 mAbanti-ICAM 1 mAbanti-intercellular adhesion molecule-1 monoclonal antibody
02
Targets
ICAM1 (Intercellular Adhesion Molecule 1)LFA-1 (Integrin αLβ2)αMβ2 (Integrin αMβ2)
Beyond the preview
Go deeper on anti-ICAM-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ICAM-1 monoclonal antibody.